Dishman Carbogen Amcis Approves Rs 75 Crore NCD Issue

Dishman Carbogen Amcis Ltd will issue up to 7,500 Non-Convertible Debentures (NCDs) worth Rs 75 crore.
The NCDs carry a 10.00% annual coupon rate, payable quarterly.

Reader Takeaway: Debt issuance secures capital; bullet repayment poses liquidity risk.

What just happened

The Board of Directors of Dishman Carbogen Amcis Limited has approved the issuance of up to 7,500 Senior, Secured, Rated, Listed, Transferable, Redeemable, Taxable Non-Convertible Debentures (NCDs) through private placement. The total issue size is Rs 75 crore.

Why this matters

This move allows the company to raise funds for its capital requirements. The NCDs offer investors a fixed return of 10.00% per annum, with the principal to be repaid in a bullet payment after 18 months. The issuance aims to diversify funding sources.

The backstory

Dishman Carbogen Amcis is a pharmaceutical manufacturer involved in contract research, development, and manufacturing services. Raising debt through NCDs is a common practice for companies to fund operations, expansion, or manage working capital.

What changes now

The company will proceed with the private placement of these NCDs, which are intended to be listed on the BSE's Wholesale Debt Market. This will add to the company's debt obligations.

Risks to watch

A key watch point is the 'bullet repayment' structure, where the entire principal amount is due at maturity after 18 months. This concentrates the repayment liability and requires careful liquidity management by the company.

Peer comparison

Companies in the pharmaceutical and chemical manufacturing sectors often raise funds through debt instruments like NCDs to finance their capital expenditure and working capital needs. The 10% coupon rate is competitive within the current market environment for similar-rated debt instruments.

Context metrics (time-bound)

The NCDs have a tenure of 18 months and a coupon rate of 10.00% per annum. The aggregate issue size is Rs 75 crore.

What to track next

Investors should monitor the company's financial health and its ability to manage the bullet repayment of principal when it becomes due in 18 months. Tracking the utilization of the funds raised will also be important.